These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 27116462

  • 21. Effective treatment of vaginal atrophy with isoflavone vaginal gel.
    Lima SM, Yamada SS, Reis BF, Postigo S, Galvão da Silva MA, Aoki T.
    Maturitas; 2013 Mar; 74(3):252-8. PubMed ID: 23312487
    [Abstract] [Full Text] [Related]

  • 22. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors.
    Davis SR, Robinson PJ, Jane F, White S, White M, Bell RJ.
    J Clin Endocrinol Metab; 2018 Nov 01; 103(11):4146-4154. PubMed ID: 30239842
    [Abstract] [Full Text] [Related]

  • 23. Intravaginally applied oxytocin improves post-menopausal vaginal atrophy.
    Al-Saqi SH, Uvnäs-Moberg K, Jonasson AF.
    Post Reprod Health; 2015 Sep 01; 21(3):88-97. PubMed ID: 25995333
    [Abstract] [Full Text] [Related]

  • 24. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study.
    Chompootaweep S, Nunthapisud P, Trivijitsilp P, Sentrakul P, Dusitsin N.
    Clin Pharmacol Ther; 1998 Aug 01; 64(2):204-10. PubMed ID: 9728901
    [Abstract] [Full Text] [Related]

  • 25. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women.
    Goldstein I, Alexander JL.
    J Sex Med; 2005 Sep 01; 2 Suppl 3():154-65. PubMed ID: 16422792
    [Abstract] [Full Text] [Related]

  • 26. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
    Palacios S, Castelo-Branco C, Cancelo MJ, Vázquez F.
    Maturitas; 2005 Feb 14; 50(2):98-104. PubMed ID: 15653006
    [Abstract] [Full Text] [Related]

  • 27. Short and long-term effect of polycarbophil vaginal gel on vaginal atrophy of peri- and post-menopausal women. The TRIPLE study.
    Cagnacci A, Franco Barattini D, Casolati E, Mangrella M, Piccolo E, Piazza R, Pecoroni A, Rosu S, Cristian Pătrașcu L.
    Eur J Obstet Gynecol Reprod Biol; 2024 Aug 14; 299():303-308. PubMed ID: 38950453
    [Abstract] [Full Text] [Related]

  • 28. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women.
    Bygdeman M, Swahn ML.
    Maturitas; 1996 Apr 14; 23(3):259-63. PubMed ID: 8794418
    [Abstract] [Full Text] [Related]

  • 29. One-year treatment persistence with local estrogen therapy in postmenopausal women diagnosed as having vaginal atrophy.
    Portman D, Shulman L, Yeaw J, Zeng S, Uzoigwe C, Maamari R, Iyer NN.
    Menopause; 2015 Nov 14; 22(11):1197-203. PubMed ID: 25944522
    [Abstract] [Full Text] [Related]

  • 30. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
    Al-Baghdadi O, Ewies AA.
    Climacteric; 2009 Apr 14; 12(2):91-105. PubMed ID: 19117185
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy.
    Crandall C.
    J Womens Health (Larchmt); 2002 Dec 14; 11(10):857-77. PubMed ID: 12626086
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
    Constantine GD, Simon JA, Pickar JH, Archer DF, Kushner H, Bernick B, Gasper G, Graham S, Mirkin S, REJOICE Study Group.
    Menopause; 2017 Apr 14; 24(4):409-416. PubMed ID: 27922936
    [Abstract] [Full Text] [Related]

  • 36. Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis.
    Marx P, Schade G, Wilbourn S, Blank S, Moyer DL, Nett R.
    Maturitas; 2004 Jan 20; 47(1):47-54. PubMed ID: 14706765
    [Abstract] [Full Text] [Related]

  • 37. Effect of estradiol vaginal gel on vaginal atrophy in postmenopausal women: A randomized double-blind controlled trial.
    Tanmahasamut P, Jirasawas T, Laiwejpithaya S, Areeswate C, Dangrat C, Silprasit K.
    J Obstet Gynaecol Res; 2020 Aug 20; 46(8):1425-1435. PubMed ID: 32715556
    [Abstract] [Full Text] [Related]

  • 38. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis.
    Dorr MB, Nelson AL, Mayer PR, Ranganath RP, Norris PM, Helzner EC, Preston RA.
    Fertil Steril; 2010 Nov 20; 94(6):2365-8. PubMed ID: 20466363
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Local oestrogen for vaginal atrophy in postmenopausal women.
    Suckling J, Lethaby A, Kennedy R.
    Cochrane Database Syst Rev; 2006 Oct 18; (4):CD001500. PubMed ID: 17054136
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.